Q-omics provides the consensus-scored MAP1LC3B2 profile across patient tissues and cancer cell-line models. MAP1LC3B2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MAP1LC3B2 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, MAP1LC3B2 RNA expression shows 18,245 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRP, and ACC as cancer lineages where MAP1LC3B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP1LC3B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP1LC3B2 survival associations across molecular data types. MAP1LC3B2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP1LC3B2 RNA expression–survival associations across cancer types. High MAP1LC3B2 expression shows unfavorable associations in LIHC, ACC, STAD, UCEC and BLCA, but favorable associations in MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MAP1LC3B2 RNA expression.
This table summarizes MAP1LC3B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MAP1LC3B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP1LC3B2 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRP, HNSC, KIRC and CHOL. The KIRP box plot shows higher MAP1LC3B2 RNA expression in tumor versus normal tissue (log2 FC = +0.724, t-test p < 0.001).
This table shows molecular features associated with MAP1LC3B2 in patient tissues and cancer cell lines. In patient samples, MAP1LC3B2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP1LC3B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
